CLINICAL TRIAL: RANDOMIZED, DOUBLE-BLIND, CONTROLLED, PHASE II TRIAL OF CTLA4IG

$8,479M01FY2010RRNIH

Feinstein Institute For Medical Research, Manhasset NY

Investigators

Linked publications & trials

Paper 38128487 Paper 36931560 Paper 34098868 Paper 32125612 Paper 32007604 Paper 31207847 Paper 30538698 Paper 30160325 Paper 30126815 Paper 29744804 Paper 29379754 Paper 29111405 Paper 29056491 Paper 28992395 Paper 28348381 Paper 27998778 Paper 27866270 Paper 27190281 Paper 27093218 Paper 27067129 Paper 26745211 Paper 26478573 Paper 26377152 Paper 26366528 Paper 26299293 Paper 26275927 Paper 26220042 Paper 25833103 Paper 25765593 Paper 25567423 Paper 25559892 Paper 25532972 Paper 25461821 Paper 25392520 Paper 25277095 Paper 25178743 Paper 25081550 Paper 25042156 Paper 24867148 Paper 24790207 Paper 24736699 Paper 24685285 Paper 24684005 Paper 24650451 Paper 24549105 Paper 24321710 Paper 24290461 Paper 24231056 Paper 24120303 Paper 23904442 Paper 23851068 Paper 23830668 Paper 23813330 Paper 23796123 Paper 23726669 Paper 23671030 Paper 23618747 Paper 23483477 Paper 23472921 Paper 23463023 Paper 23042117 Paper 23036958 Paper 22871914 Paper 22858406 Paper 22836227 Paper 22802056 Paper 22740289 Paper 22611237 Paper 22585664 Paper 22488952 Paper 22427713 Paper 22406209 Paper 22402993 Paper 22368724 Paper 22344220 Paper 22329475 Paper 22074915 Paper 22068892 Paper 22045982 Paper 21953418 Paper 21939612 Paper 21911837 Paper 21775751 Paper 21681774 Paper 21636134 Paper 21530178 Paper 21515903 Paper 21457682 Paper 21310077 Paper 21285521 Paper 21248735 Paper 21218565 Paper 21216271 Paper 21185230 Paper 21148333 Paper 21084552 Paper 20965251 Paper 20960466 Paper 20887874 Paper 20886575

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project is designed to test whether addition of Abatacept to a 24-week induction protocol involving cyclophosphamide followed in turn by azathioprine can induce remission with greater frequency than treatment with cyclophosphamide and azathioprine alone. Secondary objectives are to determine the safety of the agent, the durability of the response when the immunosuppressive medications are stopped and the partial response rate. Finally, a third secondary objective is to ascertain whether the Abatacept enables greater response to vaccinations compared to therapy with cyclophosphamide alone.

View original record on NIH RePORTER →